Etoposide in Wegener's granulomatosis

ENT manifestations of Wegeners granulomatosis.

Wegeners granulomatosis is a necrotizing granulomatous vasculitis with multisystemic involvement. We present two cases of Wegener's presenting with otological manifestations as the first symptom. These symptoms are subtle and diagnosis may be easily overlooked. Hence a high index of suspicion is required. Early diagnosis and treatment goes a long way in improving the outcomes and in preventing ...

Neutrophil chemotaxis in Wegeners granulomatosis and idiopathic pulmonary fibrosis

Background: The presence of anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener’s granulomatosis (WG), implicate the neutrophil as a key effector cell. Previous studies have reported elevated neutrophil counts in the lung although the determinants of neutrophil chemotaxis in the WG lung are unknown. Methods: BALF cell counts, myeloperoxidase (MPO) and chemokines were measured in 27 patient...

The Role of Anca and Anti-gbm Antibodies in Pulmonary- Renal Syndrom Due to Wegeners Granulomatosis

Pulmonary-renal syndrome (PRS) is defined as a diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. We present a retrospective study of 22 consecutive patients with Wegener’s granulomatosis (WG). Logistic regression analysis and a Wilcoxon test were included in the statistics. Survival time death risk were assessed using the Kaplan-Meier estimator and the Cox proportional haz...

Gene Polymorhisms of the Interleukin-10, Angiotensin-Converting Ensyme and Transforming Growth Factor-β1 Genes in Granulomatous Disorders, Pulmonary Sarcoidosis and Wegeners Granulomatosis

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia

Background: Gestational trophoblastic neoplasia (GTN) originates from placental trophoblast and is a highly chemosensitive and curable gynecologic malignancy. The present study was conducted to evaluate the effectiveness and safety of EMA/EP (etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin) regimen in the treatment of high-risk GTN as well as patients’ outcome.  &nb...